Theravance Biopharma Inc Cash Flow Reinvestment Rate

Latest as of June 2025: 0.17x

Theravance Biopharma Inc cash flow reinvestment rate. Theravance Biopharma Inc (TBPH) has a Cash Flow Reinvestment Rate of 0.17x as of June 2025, reinvesting $36.29 Million (capex $34.00K plus investments $-36.26 Million) from operating cash flow of $208.07 Million. Explore Theravance Biopharma Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.17x

(Capex + Investments) / Operating CF

Total Reinvested

$36.29 Million

Capex + Investments

Operating Cash Flow

$208.07 Million

USD

Capital Expenditures

$34.00K

USD

Cash Flow Reinvestment Rate of Theravance Biopharma Inc (2025–2025)

Cash flow reinvestment rate of Theravance Biopharma Inc from 2025 to 2025. Historical reinvestment intensity for Theravance Biopharma Inc across 1 annual periods. Explore Theravance Biopharma Inc (TBPH) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Theravance Biopharma Inc Cash Flow Reinvestment Rate by Year (2025–2025)

Theravance Biopharma Inc cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for Theravance Biopharma Inc. For the full cash flow conversion analysis, see Theravance Biopharma Inc cash conversion from operations.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.44x	$105.28 Million	$238.54 Million	$42.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow